Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia

作者: Maribel Acosta-Tejeda , Héctor Baptista-González , Fany Rosenfeld-Mann , Rocio Trueba-Gómez , Ethel García-Latorre

DOI: 10.1016/J.THROMRES.2011.05.019

关键词:

摘要: Abstract Introduction The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), TAFIa plasma levels are associated with preeclampsia. Materials Methods In a case-control study design, we evaluated preeclampsia patients women uncomplicated pregnancies. TAFI were determined by real-time PCR method, established chromogenic assay. Results We included 87 in each group. the group 20.4 μg/mL (CI 95% 17.3-23.5), while control group, they significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There no differences genotype distribution or allelic frequency of between two groups. controls heterozygous for G505A polymorphism, values 22.8 (16.7-28.9 μg/mL) 13.2 (11.3-15.0 μg/mL, 0.019), respectively. homozygous polymorphism 25.7 (18.7-32.6 μg/mL) 13.5 (1.6-21.9 μg/mL, 0.041), C1040T G-438A wild type polymorphisms, 18.3 (12.5-23.9 μg/mL) 11.5 (9.9-35.0, 0.033), 19.4 (10.9-27.9 μg/mL) 12.5 (10.8-14.2 μg/mL, 0.006), respectively, without other genotypes. Conclusions Preeclampsia itself may be responsible increase rather than presence polymorphisms.

参考文章(24)
P. Chetaille, M. C. Alessi, D. Kouassi, P. E. Morange, I. Juhan-Vague, Plasma TAFI antigen variations in healthy subjects. Thrombosis and Haemostasis. ,vol. 83, pp. 902- 905 ,(2000) , 10.1055/S-0037-1613941
Yinghong Zhang, Yu Hu, Tao Guo, Wenning Wei, Xiaoping Zhang, Thrombin activatable fibrinolysis inhibitor in preeclmapsia and gestational hypertension throughout the gestation Journal of Huazhong University of Science and Technology [Medical Sciences]. ,vol. 28, pp. 140- 143 ,(2008) , 10.1007/S11596-008-0206-6
D.L. Eaton, B.E. Malloy, S.P. Tsai, W. Henzel, D. Drayna, Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. Journal of Biological Chemistry. ,vol. 266, pp. 21833- 21838 ,(1991) , 10.1016/S0021-9258(18)54713-X
M. P. M. De Maat, M. W. J. C. Jansen, E. T. M. Hille, H. L. Vos, K. W. M. Bloemenkamp, S. Buitendijk, F. M. Helmerhorst, J. W. Wladimiroff, R. M. Bertina, C. J. M. De Groot, Preeclampsia and its interaction with common variants in thrombophilia genes. Journal of Thrombosis and Haemostasis. ,vol. 2, pp. 1588- 1593 ,(2004) , 10.1111/J.1538-7836.2004.00861.X
Joan Montaner, Marc Ribó, Jasone Monasterio, Carlos A. Molina, José Alvarez-Sabín, Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke Stroke. ,vol. 34, pp. 1038- 1040 ,(2003) , 10.1161/01.STR.0000063139.06585.45
Takashi Watanabe, Hisanori Minakami, Yoichi Sakata, Shigeki Matsubara, Ikuo Sato, Mitsuaki Suzuki, Changes in Activity of Plasma Thrombin Activatable Fibrinolysis Inhibitor in Pregnancy Gynecologic and Obstetric Investigation. ,vol. 58, pp. 19- 21 ,(2004) , 10.1159/000077178
Evelien Heylen, Predrag Miljic, Johan Willemse, Valentina Djordjevic, Dragica Radojkovic, Milica Colovic, Ivo Elezovic, Dirk Hendriks, Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia Thrombosis Research. ,vol. 124, pp. 427- 432 ,(2009) , 10.1016/J.THROMRES.2009.01.005
Luci Maria SantAna Dusse, Alan J Cooper, Bashir A Lwaleed, None, Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia? Clinica Chimica Acta. ,vol. 378, pp. 1- 6 ,(2007) , 10.1016/J.CCA.2006.10.014
Hatem Mousa, Colin Downey, Zarko Alfirevic, Cheng-Hock Toh, Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thrombosis and Haemostasis. ,vol. 92, pp. 1025- 1031 ,(2004) , 10.1160/TH04-06-0387
İnci Alacacıoğlu, Mehmet Ali Özcan, Ahmet Alacacıoğlu, Mesut Polat, Faize Yüksel, Fatih Demirkan, Özden Pişkin, Yigit Özgenç, Hayri Güner Özsan, Bulent Undar, Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women Thrombosis Research. ,vol. 114, pp. 155- 159 ,(2004) , 10.1016/J.THROMRES.2004.05.012